Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma.

摘要: Nasopharyngeal carcinoma (NPC) is a squamous cell with proclivity for systemic dissemination, leading many patients to present advanced-stage disease and fail available treatments. There notable lack of targeted therapies NPC, despite working knowledge multiple proteins integral roles in NPC cancer biology. These include EZH2, Snail, eIF4E, IMPDH, which are all overexpressed correlated poor prognosis. known be modulated by ribavirin, an FDA-approved Hepatitis C antiviral that has recently been repurposed as promising therapeutic several solid hematologic malignancies. Here, we investigated the potential ribavirin anti-cancer agent five human lines. Using cellular growth assays, flow cytometry, BrdU proliferation scratch wound invasion show vitro decreases proliferation, migration, promotes cycle arrest death. Modulation mTOR, cyclin D1 were observed western blots enzymatic activity assays response treatment. As monotherapy, reduced flank tumor xenograft models vivo. Most importantly, demonstrate enhanced effects radiation therapy, central component treatment, both Our work suggests responds ribavirin-mediated mTOR changes positions clinical evaluation addition our treatment armamentarium.